- Home
- TLPH vs RDHL Comparison
TLPH vs RDHL Comparison
Compare TLPH & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | RDHL |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 3.9M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLPH | RDHL |
|---|---|---|
| Price | $1.04 | $1.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 365.3K | 75.2K |
| Earning Date | 11-12-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $28,000.00 | ★ $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | $14,267.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $0.38 | $1.01 |
| 52 Week High | $1.57 | $7.30 |
Technical Indicators
Market Signals| Indicator | TLPH | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 36.10 | 48.65 |
| Support Level | $1.20 | $1.15 |
| Resistance Level | $1.25 | $1.24 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 1.69 | 41.96 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.